Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-13
2005-09-13
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S444000, C514S464000, C514S468000, C546S284100, C549S060000, C549S078000, C549S435000, C549S458000, C549S466000
Reexamination Certificate
active
06943182
ABSTRACT:
The invention relates to cyclopentabenzofuran derivatives, process for their preparation, the use of cyclopentabenzofuran derivatives for the production of a medicament for the therapy of NF-κB-dependent diseases and medicaments which contain the cyclopentabenzofuran derivatives.
REFERENCES:
patent: 4539414 (1985-09-01), King et al.
patent: 5274167 (1993-12-01), Lange et al.
patent: 5702710 (1997-12-01), Charpentier et al.
patent: 0709382 (1996-01-01), None
patent: 9604284 (1996-02-01), None
patent: 9708161 (1997-06-01), None
Adams C. Synthetic Communications, 1984, 14(10): 955-9.
Gribble GW and Nutaitis CF. Organic Preparations and Procedures International (1985), 17(4-5), 317-320.
Baldwin Jr., A. S., “The NF-κB and IκB Proteins: New Discoveries and Insights”, Annu. Rev. Immunol., 14: 649-681 (1996).
Barnes, P. J.; Adcock, I. M., “NF-κB: A Pivotal Role in Asthma and a New Target for Therapy”, TIPS, 18: 46-50 (Feb. 1997).
Baeuerle, P. A.; Henkel, T., “Function an Activation of NF-κB in the Immune System”, Annu. Rev. Immunol., 12: 141-179 (1994).
Cui, B.; Chai, H.; Santisuk, T.; Reutrakul, V.; Farnsworth, N. R.; Cordell, G. A.; Pezzuto, J. M.; Kinghorn, A. D., “Novel Cytotoxic 1H-Cyclopenta[b]benzofuran Ligans fromAglaia elliptica”, Tetrahedron, 53(52): 17625-17632 (1997).
Davey, A. E.; Schaeffer, M. J.; Taylor, R. J. K., “Synthesis of the Novel Anti-leukaemic Tetrahydrocyclopenta[b]benzofuran, Rocalamide and Related Synthetic Studies”, J. Chem. Soc. Perkin Trans. 1, pp. 1657-2665 (1992).
Davey, A. E., Schaeffer, M. J., and Taylor, R. J. K., “Synthesis of the Novel Anti-leukaemic Tetrahydrocyclopenta[b]benzofuran, Rocaglamide”, J. Chem. Soc. Commun., pp. 1137-1139 (1991).
Dumontet, V., Thoison, O., Omobuwajo, O. R., Martin, M.-T., Perromat, G., Chiaroni, A., Riche, C., Pais, M., and Sevenet, T., “New Nitrogenous and Aromatic Derivatives fromAglaia argenteaandA. forbesii”, Tetrahedron 52(20): 6931-6942 (1996).
Dieter Von, A.; Bömer, B.; Grosser, R.; Lange, W., “Neue Chirale Stationäre Polyamid-Phasen für die Chromatographische Enantiomerentrennung”, Angew. Chem., 103(12): 1685-1687 (1991).
Goldfeld, A. E.; Doyle, C.; Maniatis, T., “Human Tumor Necrosis Factor α Gene Regulation by Virus and Lipopolysaccharide”, Proc. Natl. Acad. Sci. USA, 87: 9769-9773.
Güssregen, B.; Fuhr, M.; Nugroho, B. W.; Wray, V.; Witte, L.; Proksch, P., “New Insecticidal Rocaglamide Derivatives from Flowers ofAglaia odorata”, Z. Naturforsch., C: Biosci., 52(5/6): 339-344 (1997).
Ishibashi, F.; Satasook, C.; Isman, M. B.; Towers, G. H. N., “Insecticidal 1H-Cyclopentatetrahydro[b]benzofurans from Aglaia odorata”, Phytochemistry, 32(2): 307-310 (1993).
Lenardo, M.J.; Baltimore, D., “NF-κB: a Pleiotropic Mediator of Inducible and Tissue-Specific Gene Control”, Cell, 58: 227-229 (1989).
Loveys, B.; Milborrow, B. V., “Hydroxylation of Methyl Abscisate and the Formation of Three β-D-Glucosides”, Phytochemistry, 31(1): 67-72 (1992).
Lu King, M.; Chiang, C.-C.; Ling, H.-C.; Fujita, E.; Ochiai, M.; McPhail, A. T., “X-Ray Crystal Structure of Rocaglamide, a Novel Antileukemic 1H-Cyclopenta[b]benzofuran fromAglaia elliptifolia”, J. Chem. Soc., Chem. Commun., pp. 1150-1151 (1982).
Nugroho, B. W.; Edrada, R. A.; Güssregen, B.; Wray, V.; Witte, L.; Proksch, P., “Insecticidal Rocaglamide Derivatives fromAglaia Duppereana”, Phytochemistry, 44(8): 1455-1461 (1997).
Oeth, P.; Parry, G. C. N.; Mackman, N., “Regulation of the Tissue Factor Gene in Human Monocytic Cells. Role of AP-1, NF-κB/Rel, and Sp1 Proteins in Uninduced and Lipopolysacharide-Induced Expression”, Arteriosclerosis, Thrombosis, and Vascular Biology, 17(2): 365-374 (Feb. 1997).
Ohse, T.; Ohba, S.; Yamamoto, T.; Koyano, T.; Umezawa, K., “Cyclopentabenzofuran Lignan Protein Synthesis Inhibitors fromAglaia odorata”, J. Nat. Prod., 59: 650-652 (1996).
Read, M. A.; Whitley, M. Z.; Gupta, S.; Pierce, J. W.; Best, J.; Davis, R. J.; Collins, T., “Tumor Necrosis Factor α-Induced E-Selectin Expression is Activated by the Nuclear Factor-κB and c-JUN N-terminal Kinase/p38 Mitogen-activated Protein Kinase Pathways”, J. Biol. Chem., 272(5): 2753-2761 (Jan. 1997).
Satasook, C.; Isman, M. B.; Wiriyachitra, P., “Activity of Rocaglamide, an Insecticidal Natural Product, Against the Variegated Cutworm,Peridroma saucia(Lepidoptera: Noctuidae)”, Pestic. Sci., 36: 53-58 (1992).
Transfection of Mammalian Cells in Culture, L. G. Davis et al., Basic Methods in Molecular Biology, Elsevier Sci. Publishing Co., New York (1986).
Greene, T. W.; Wuts, P. G. M., Protective Groups in Organic Synthesis, 2ndEd., John Wiley & Sons, New York (1991).
Antonicek Horst-Peter
Baumgarten Jörg
Guarnieri Walter
Jaetsch Thomas
Kretschmer Axel
Bayer Aktiengesellschaft
Huang Evelyn Mei
Pellegrino Susan M.
LandOfFree
Cyclopentabenzofuran derivatives and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclopentabenzofuran derivatives and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopentabenzofuran derivatives and their use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3373448